Cargando…
Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Anti-HMG CoA) Myopathy With Cardiac Involvement: Presentation, Diagnosis, and Management
Immune-mediated necrotizing myopathy (IMNM) is categorized into three groups: anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) IMNM, anti-signal recognition particle (SRP) IMNM, and seronegative IMNM. Cardiac involvement has been reported in a significant segment of patients with IMNM of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004697/ https://www.ncbi.nlm.nih.gov/pubmed/35425681 http://dx.doi.org/10.7759/cureus.23125 |
_version_ | 1784686315977048064 |
---|---|
author | Liu, Lisa Tessier, Steven Ido, Firas Longo, Santo Nanda, Sudip |
author_facet | Liu, Lisa Tessier, Steven Ido, Firas Longo, Santo Nanda, Sudip |
author_sort | Liu, Lisa |
collection | PubMed |
description | Immune-mediated necrotizing myopathy (IMNM) is categorized into three groups: anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) IMNM, anti-signal recognition particle (SRP) IMNM, and seronegative IMNM. Cardiac involvement has been reported in a significant segment of patients with IMNM of the anti-SRP type. Emerging evidence now suggests that cardiac involvement is also implicated in the anti-HMGCR subgroup. In this report, we present a case of anti-HMGCR IMNM with cardiac involvement demonstrated by elevated troponin levels, a low ejection fraction of 40%, and regional wall motion abnormalities in the inferior, inferolateral, anteroseptal, inferoseptal, and anterolateral myocardial walls, as visualized on echocardiography. These findings markedly improved after treatment with intravenous immunoglobulin (IVIG) and prednisone. This case and other recent reports highlight the need for a cardiac workup in patients diagnosed with anti-HMGCR IMNM. |
format | Online Article Text |
id | pubmed-9004697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-90046972022-04-13 Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Anti-HMG CoA) Myopathy With Cardiac Involvement: Presentation, Diagnosis, and Management Liu, Lisa Tessier, Steven Ido, Firas Longo, Santo Nanda, Sudip Cureus Cardiology Immune-mediated necrotizing myopathy (IMNM) is categorized into three groups: anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) IMNM, anti-signal recognition particle (SRP) IMNM, and seronegative IMNM. Cardiac involvement has been reported in a significant segment of patients with IMNM of the anti-SRP type. Emerging evidence now suggests that cardiac involvement is also implicated in the anti-HMGCR subgroup. In this report, we present a case of anti-HMGCR IMNM with cardiac involvement demonstrated by elevated troponin levels, a low ejection fraction of 40%, and regional wall motion abnormalities in the inferior, inferolateral, anteroseptal, inferoseptal, and anterolateral myocardial walls, as visualized on echocardiography. These findings markedly improved after treatment with intravenous immunoglobulin (IVIG) and prednisone. This case and other recent reports highlight the need for a cardiac workup in patients diagnosed with anti-HMGCR IMNM. Cureus 2022-03-13 /pmc/articles/PMC9004697/ /pubmed/35425681 http://dx.doi.org/10.7759/cureus.23125 Text en Copyright © 2022, Liu et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Cardiology Liu, Lisa Tessier, Steven Ido, Firas Longo, Santo Nanda, Sudip Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Anti-HMG CoA) Myopathy With Cardiac Involvement: Presentation, Diagnosis, and Management |
title | Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Anti-HMG CoA) Myopathy With Cardiac Involvement: Presentation, Diagnosis, and Management |
title_full | Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Anti-HMG CoA) Myopathy With Cardiac Involvement: Presentation, Diagnosis, and Management |
title_fullStr | Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Anti-HMG CoA) Myopathy With Cardiac Involvement: Presentation, Diagnosis, and Management |
title_full_unstemmed | Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Anti-HMG CoA) Myopathy With Cardiac Involvement: Presentation, Diagnosis, and Management |
title_short | Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Anti-HMG CoA) Myopathy With Cardiac Involvement: Presentation, Diagnosis, and Management |
title_sort | anti-3-hydroxy-3-methylglutaryl coenzyme a reductase (anti-hmg coa) myopathy with cardiac involvement: presentation, diagnosis, and management |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004697/ https://www.ncbi.nlm.nih.gov/pubmed/35425681 http://dx.doi.org/10.7759/cureus.23125 |
work_keys_str_mv | AT liulisa anti3hydroxy3methylglutarylcoenzymeareductaseantihmgcoamyopathywithcardiacinvolvementpresentationdiagnosisandmanagement AT tessiersteven anti3hydroxy3methylglutarylcoenzymeareductaseantihmgcoamyopathywithcardiacinvolvementpresentationdiagnosisandmanagement AT idofiras anti3hydroxy3methylglutarylcoenzymeareductaseantihmgcoamyopathywithcardiacinvolvementpresentationdiagnosisandmanagement AT longosanto anti3hydroxy3methylglutarylcoenzymeareductaseantihmgcoamyopathywithcardiacinvolvementpresentationdiagnosisandmanagement AT nandasudip anti3hydroxy3methylglutarylcoenzymeareductaseantihmgcoamyopathywithcardiacinvolvementpresentationdiagnosisandmanagement |